Latest news with #ShaikhFahadbinKhalifabinSalmanAlKhalifa
Biz Bahrain
31-01-2025
- Health
- Biz Bahrain
RMS signs cooperation agreement with Siemens Healthineers
The Royal Medical Services (RMS) signed a cooperation agreement with Siemens Healthineers, on the sidelines of the 50th edition of the Arab Health Conference and Exhibition. The agreement, signed by Brigadier General Dr. Shaikh Fahad bin Khalifa bin Salman Al Khalifa, RMS Commander and Chairman of the Supreme Committee for Overseas Treatment, and Vivek Kanade, CEO for the Middle East and Africa at Siemens, coincides with the launch of the NAEOTOM Alpha PCCT at the Mohammed bin Khalifa bin Salman Al Khalifa Specialised Cardiac Centre, the first of its kind in the Middle East. Brig. Gen. Dr. Shaikh Fahad highlighted RMS's commitment to advanced diagnostics and cardiac care. The NAEOTOM Alpha PCCT offers high-precision imaging with minimal radiation, enabling non-invasive cardiac diagnostics and reducing the need for catheterisation. BNA(R)
Biz Bahrain
27-01-2025
- Health
- Biz Bahrain
RMS adopts Sentiva technology to treat advanced epilepsy cases
As part of ongoing efforts to enhance and advance treatment methods through the adoption of the latest technologies, Brigadier General Dr. Shaikh Fahad bin Khalifa bin Salman Al Khalifa, Commander of the Royal Medical Services (RMS), announced the adoption of 'Sentiva' technology as an effective and innovative tool for the treatment of epilepsy. The technology, a first of its kind, is now being utilised in Bahrain and the Gulf region. A medical team from the Royal Medical Services at the Military Hospital, comprising Dr. Mohammed Al Mahraqi, Consultant in Oral, Maxillofacial, and Neck Surgery, Dr. Mohammed Al Shihabi, Consultant in Ear, Nose, and Throat Surgery, and Dr. Raafat Hammad Sarour, Consultant in Paediatric Neurology, successfully treated two advanced epilepsy cases using Sentiva technology. The team conducted comprehensive evaluations and diagnoses of the patients, both of whom were diagnosed with advanced epilepsy that did not respond to medication. After thorough assessments and considering international protocols and the individual characteristics of the disease, the team developed a tailored treatment plan. The treatment involved performing surgical procedures to implant electrodes using the 'Sentiva' device, followed by placing the neurostimulator under the skin, typically in the chest area. Post-surgery, the neurostimulation device was programmed and adjusted to meet the specific needs of each patient. The procedure took approximately one hour and was successfully completed, enabling the patients to resume their normal lives without experiencing recurrent seizures. 'Sentiva' is among the most advanced medical technologies, using a sophisticated mechanism to stimulate the vagus nerve to reduce seizure frequency, particularly in patients unresponsive to conventional treatments. The device allows physicians to adjust stimulation levels to suit individual patient needs, ensuring long-term therapeutic benefits. BNA(R)
